Skip to main
MET

MetLife (MET) Stock Forecast & Price Target

MetLife (MET) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

MetLife is well positioned to compound earnings because its largest businesses—Group Benefits and RIS—contribute about 52% of 2025 adjusted earnings and benefit from scale, market leadership, and operating leverage. The company also has attractive growth engines in Asia, Latin America, and MIM, with capital-light mix shift, strong ROE of 16% in 2025 and 17% in 1H26, and a target of 4-7% near-term top-line growth in Group Benefits supporting a higher-quality earnings profile. Management’s AI and reinsurance initiatives, including Chariot Re’s capital raises and MIM’s AUM rising from about $625B to ~$750B, add fee upside, while disciplined underwriting and a favorable interest-rate backdrop support durable free cash flow and further ROE expansion.

Bears say

MetLife is exposed to meaningful downside from lower long-term interest rates, credit spread widening, and market volatility, all of which can pressure spread income, investment results, and liability stability across its large insurance and retirement books. Its earnings mix is also vulnerable because about 52% of 2025 adjusted earnings comes from Group Benefits and RIS, while Asia, Latin America, EMEA, and investment management add geographic and market-linked risks that can be amplified by FX, regulation, and competition. Even though the stock screens inexpensive at about 9.6x 2026E P/E and 8.8x 2027E P/E, that valuation discount reflects real concerns around alternative asset returns, wage and employment softness, and the sustainability of favorable mortality trends.

MetLife (MET) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MetLife and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MetLife (MET) Forecast

Analysts have given MetLife (MET) a Buy based on their latest research and market trends.

According to 12 analysts, MetLife (MET) has a Buy consensus rating as of Oct 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $108.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $108.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MetLife (MET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.